Sign in
Not yet recruitingNo phase

Metronidazole- Versus Tinidazole-Based Bismuth Quadruple Therapy for Helicobacter Pylori Eradication

Key facts

Who runs it
University of Medicine and Pharmacy at Ho Chi Minh City
Where
Vietnam1 site in 1 countryChoose a country to see its sites
Trial code
Status
Not yet recruiting
People taking part
600 people, planned
Started
27 Jul 2026
Expected to end
27 Dec 2027
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Metronidazole
  • Tinidazole 500mg
  • tetracyline
  • Bismuth Subcitrate
  • esomeprazole 40 mg
Record updated
5 August 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 11 criteriaShow less

Who can take part

  • Adults aged 18 years or older
  • Confirmed Helicobacter pylori infection
  • Willing and able to provide written informed consent

Who cannot take part

  • Previous H. pylori eradication therapy
  • Previous gastric surgery
  • Use of antibiotics within the previous 4 weeks
  • Gastrointestinal malignancy
  • Stage IV or V chronic kidney disease
  • Known allergy to any study medication
  • Pregnancy or breastfeeding
  • Liver cirrhosis

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This randomized, open-label clinical trial will compare two bismuth-containing quadruple therapies for the first-line treatment of Helicobacter pylori infection. Adults aged 18 years or older with confirmed H. pylori infection who have not previously received eradication treatment will be randomly assigned in a 1:1 ratio to receive either a metronidazole-based regimen or a tinidazole-based regimen for 14 days. Both regimens will also include esomeprazole, tetracycline, and bismuth subcitrate.

Read full original descriptionShow less

The main purpose of the study is to determine whether the tinidazole-based regimen is not inferior to the metronidazole-based regimen in achieving successful H. pylori eradication. Eradication will be assessed after treatment using a carbon-13 urea breath test or an endoscopic urease test. The study will also compare adverse effects and treatment tolerability between the two groups. The results may help clinicians select the more appropriate nitroimidazole for bismuth quadruple therapy in routine clinical practice.

The 2 groups in the trial

  • Metronidazole-Based Bismuth Quadruple TherapyExisting treatment, for comparison

    Treatment: Metronidazole, tetracyline, Bismuth Subcitrate, and esomeprazole 40 mg

  • Tinidazole-Based Bismuth Quadruple TherapyTreatment being tested

    Treatment: Tinidazole 500mg, tetracyline, Bismuth Subcitrate, and esomeprazole 40 mg

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Comparison of Metronidazole- and Tinidazole-Based Bismuth Quadruple Regimens for Helicobacter Pylori Eradication
Record updated
5 August 2026